BiotechTube

RHB-204 + Placebo

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pulmonary Mycobacterium Avium Complex Infection

Conditions

Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases

Trial Timeline

Dec 1, 2020 → Aug 28, 2023

NCT ID
NCT04616924

About RHB-204 + Placebo

RHB-204 + Placebo is a phase 3 stage product being developed by RedHill Biopharma for Pulmonary Mycobacterium Avium Complex Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT04616924. Target conditions include Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04616924Phase 3Terminated

Competing Products

20 competing products in Pulmonary Mycobacterium Avium Complex Infection

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
44
macitentan 10 mgBML, Inc.Phase 3
76
tadalafil + tadalafilEli LillyPhase 3
77
CS1 AdministrationCereno ScientificPhase 2
47
CS1Cereno ScientificPre-clinical
18
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
44
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
52
DS-1040b + Placebo + EnoxaparinDaiichi SankyoPhase 1/2
41
DS-9231 + PlaceboDaiichi SankyoPhase 2
52
RegadenosonAstellas PharmaPre-clinical
23
Reldesemtiv + PlaceboAstellas PharmaPhase 2
52
MonteplaseEisaiApproved
85
lysozyme 90 mg + PlaceboEisaiApproved
85
Prednisolone + VoriconazoleCiplaPhase 2/3
65
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)Eli LillyPhase 2
52
tadalafil and ambrisentan upfront combination therapyEli LillyApproved
85

Other Products from RedHill Biopharma

RHB-102 + Placebo Oral TabletPhase 3
69
RHB-105 + PlaceboPhase 3
69
RHB-104 + PlaceboPhase 3
69
RHB-105 + Active ComparatorPhase 3
69
RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)Phase 3
69